Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Effect of Physical Activity and/or Probiotics on Body Composition and Physiological Parameters in Women

NCT06746220 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2024-09-16
Last updated
2025-12-30

Condition(s) studied

Healthy Women

Investigational drug(s) / intervention(s)

Microbiota sampleSalivary sampleQuality of life questionnairesNutritional evaluationAssessment of physical healthPhysical activityTreatment with placebo or probiotic

Microbiota sample: Microbiota sample: one sample at inclusion and one sample at the end of the study

Salivary sample: Salivary sample: one sample at inclusion and one sample at the end of the study. In the morning, on an empty stomach.

Quality of life questionnaires: Quality of life questionnaires: 5 auto-questionnaires to be filled at inclusion and at the end of the study

Nutritional evaluation: Nutritional evaluation: food diary completed by participants for 3 consecutive days at inclusion and at the end of the study

Assessment of physical health: Assessment of physical health : 3 tests to assess strength and endurance. These tests will be performed at inclusion and at the end of the study.

Physical activity: Physical activity: 2 sessions per week for 6 weeks. For each session, 45 minutes of physical activity consisting of muscle strengthening and endurance exercises.

Treatment with placebo or probiotic: Treatment with placebo or probiotic: 1 capsule per day during 42 consecutive days. In the morning, on an empty stomach with a large glass of water 20 minutes before the meal

Study summary

This is a prospective, comparative, double-blind, randomized, monocentric study.

The objective of this project is to evaluate the effects on health of probiotic supplementation (PS) with or without physical activity (PA). Participants who meet the study criteria will be randomized into 4 groups: probiotic and physical activity group (A+), probiotic and non-physical activity group (A-), placebo and physical activity group (T+), placebo and non-physical activity group (T-).

The probiotics used are Lactibiane® Reference provided by Pileje Laboratory. The study population are healthy women (university students) who do not practice sports. A total of 120 participants will participate.

At inclusion, each participant will undergo a medical examination, collect microbiota and salivary samples and perform different tests (questionnaires, assessments of strength and endurance). Then, a follow up phase will last 6 weeks. Each participant will receive a pillbox containing capsules (probiotic or placebo in a double-blind manner). Participants which randomized in the PA groups (A+ and A-) will perform 2 physical activity sessions per week for 6 weeks. At the end of this follow up phase, tests conducting during inclusion will be performed again.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: 1. Being female 2. Age ≥ 18 years old 3. Have a BMI between 18.5 and 30 kg/m2 4. Be registered as a student at the University of Orléans 5. Be non-athletic 6. Have no contraindication to the practice of physical activity 7. All participants must sign informed consent before the start of the study Exclusion Criteria: 1. Smokers \>10 cigarettes per day 2. Having treatment for a pathology at the time of inclusion 3. Taking a probiotic supplement during the last month prior to inclusion 4. Practice physical activity regularly (150 minutes/week of moderate physical activity according to the WHO) 5. Participant under guardianship or curators 6. Pregnant or breastfeeding women 7. Menopausal women 8. Allergy to any excipient known to be present in the probiotic or placebo formulation

Primary outcome measure(s)

  • Effect of physical activity on muscle mass in healthy women — Measure of muscle mass will be performed at inclusion and at the end of the study (an average of 2 months after inclusion)
    Assessment of muscle mass with an impedance meter
  • Effect of probiotic supplementation on muscle mass in healthy women — Measure of muscle mass will be performed at inclusion and at the end of the study (an average of 2 months after inclusion)
    Assessment of muscle mass with an impedance meter

Trial sites (1)

FacilityCityRegionStatus
Center Hospitalier Universitaire d'Orléans Orléans France Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06746220 on ClinicalTrials.gov ↗ ← All trials in France